<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309230</url>
  </required_header>
  <id_info>
    <org_study_id>CL-PTL 105</org_study_id>
    <nct_id>NCT01309230</nct_id>
  </id_info>
  <brief_title>Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer</brief_title>
  <official_title>Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gradalis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gradalis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II open-label trial of maintenance Vigil™ autologous tumor cell vaccine.&#xD;
      Tumor will be harvested at the time of surgical debulking (standard of medical care).&#xD;
      Subsequently, patients achieving clinical CR following primary surgical debulking and doublet&#xD;
      chemotherapy will be stratified for i) surgical stage (Stage IV or suboptimal debulking (&gt;1&#xD;
      cm residual) Stage III disease versus Stage III patients with optimal debulking (&lt;1 cm&#xD;
      residual)) and ii) post-op chemotherapy, pre-vaccine CA-125 &gt;10 ≤ 20 U/mL versus 0≤10 U/ml.&#xD;
      (Note: patients with Stage IIIc ovarian cancer will be additionally evaluated as a subset&#xD;
      using descriptive statistics only). Patients will receive 1.0 x 10^7 cells / intradermal&#xD;
      injection of gene transfected autologous tumor cells, Vigil™ once a month for up to 12 doses&#xD;
      as long as sufficient material is available. Enough harvested tissue to provide a minimum of&#xD;
      4 monthly injections will be required for entry into the study. Hematologic function, liver&#xD;
      enzymes, renal function and electrolytes will be monitored monthly. Immune function analysis&#xD;
      including ELISPOT analysis of cytotoxic T cell function to autologous tumor antigens will be&#xD;
      monitored at (≤24 hours before) tissue harvest, ≤24 hours before the first cycle of&#xD;
      chemotherapy (post debulking), ≤24 hours before the third cycle of chemotherapy (post&#xD;
      debulking), baseline (screening), prior to Vigil™ injection Months 2, 4, 6 and at EOT. The&#xD;
      dates of the last dose of chemotherapy and the administration of Vigil™ vaccine #1 will be&#xD;
      recorded. Treatment will be continued until disease recurrence or exhaustion of the patient's&#xD;
      vaccine supply. If ≥ Grade 2 toxicity by NCI Common Toxicity Criteria (excluding Grade 2&#xD;
      fever ≤ 24 hours and Grade 2 and 3 injection site reactions) develops related to study&#xD;
      treatment the vaccine dose will be reduced by 50% and continued on a monthly basis. If a&#xD;
      single patient develops ≥ Grade 3 toxicity (other than injection site reaction) related to&#xD;
      study treatment the trial will be placed on hold for reevaluation of design in discussion&#xD;
      with FDA. During this hold, no new subjects will initiate dosing, but subjects already being&#xD;
      dosed may continue dosing as scheduled if deemed clinically appropriate by the PI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite a gradual improvement in their overall survival over the past decade, approximately&#xD;
      75% of women with Stage IIIC ovarian cancer who achieve a complete clinical response will&#xD;
      relapse as will 50% of those achieving pathologic complete response at a median time of 18-24&#xD;
      months. Phase III studies of both maintenance and consolidation therapeutic interventions&#xD;
      have not translated into an overall survival advantage. Preliminary studies of immunotherapy&#xD;
      in patients with ovarian cancer suggest target accessibility (potential immunogenicity) to&#xD;
      immune mediated approaches. In an effort to overcome limitations of immunostimulatory cancer&#xD;
      vaccines, we designed a novel autologous whole cell vaccine, Vigil™, incorporating the&#xD;
      rhGMCSF transgene and the bifunctional shRNA^furin (to block proprotein conversion to active&#xD;
      TGFb1 and b2) to 1) address the inability to fully identify cancer associated antigens, 2)&#xD;
      effect antigen recognition by the immune system (i.e. antigen→immunogen), 3) enhance effector&#xD;
      potency, and 4) subvert endogenous cancer-induced immune resistance. A Phase I assessment of&#xD;
      Vigil™ vaccine in 33 advanced solid tumor patients (1 of them being a pediatric patient 15&#xD;
      years of age) receiving ≥1 vaccination (at a dose of 1.0 x 10^7 or 2.5 x 10^7&#xD;
      cells/injection/month for a maximum of 12 vaccinations) demonstrated safety of the Vigil™&#xD;
      vaccine. Furthermore, proof of principle was established in the manufactured vaccines with&#xD;
      increased mean GMCSF expression post-transfection to 1135 pg/10^6 cells/ml and knockdown of&#xD;
      furin, TGFb1 and TGFb2 at 78%, 93%, and 95%, respectively). In addition, although a Phase I&#xD;
      study, the data suggested an overall survival benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine and compare time to recurrence (TTR)</measure>
    <time_frame>Participants will be followed for life.</time_frame>
    <description>Primary Objective(s):&#xD;
• To assess time to recurrence (TTR) following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil™) vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Function</measure>
    <time_frame>Blood will be collected at baseline, Months 2, 4, 6, and EOT</time_frame>
    <description>Secondary Objectives:&#xD;
To identify and determine the effect of Vigil™ autologous tumor cell vaccine on immune surrogate markers.&#xD;
To assess the predictive potential of initial tumor infiltrating lymphocyte (TIL) and tumor associated macrophage (TAM) phenotypes.&#xD;
To enlarge the safety database of Vigil™ autologous tumor cell vaccine in patients with minimal disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Vigil™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vigil™</intervention_name>
    <description>intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)</description>
    <arm_group_label>Vigil™</arm_group_label>
    <other_name>formerly known as FANG™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Tissue Procurement Inclusion Criteria:&#xD;
&#xD;
          1. Presumptive Stage III/IV papillary serous or endometrioid ovarian cancer.&#xD;
&#xD;
          2. Per Amendment #8, treatment naïve, high risk ovarian cancer will no longer be&#xD;
             stratified, but the following information will be collected:&#xD;
&#xD;
               1. Stage IV or suboptimal (&gt;1 cm residual) Stage III disease versus Stage III&#xD;
                  patients with optimal (≤1 cm residual) disease,&#xD;
&#xD;
               2. CA-125 ≤10 U/ml versus CA-125 greater than 10 but less than or equal to 20 U/ml&#xD;
&#xD;
               3. IP chemotherapy versus IV chemotherapy&#xD;
&#xD;
          3. Availability of &quot;golf-ball&quot; size 10-30 grams tissue at time of primary surgical&#xD;
             debulking.&#xD;
&#xD;
          4. ECOG performance status (PS) 0-2 prior to tumor debulking laparotomy.&#xD;
&#xD;
          5. Ability to understand and the willingness to sign a written informed consent document&#xD;
             for tissue harvest.&#xD;
&#xD;
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Histologically confirmed Stage III/IV papillary serous or endometrioid ovarian cancer.&#xD;
&#xD;
          2. Clinically defined CR (no cancer related symptoms, normal physical examination and CT&#xD;
             scan abdomen/pelvis and CXR, and CA-125 ≤20 U/ml) following completion of primary&#xD;
             surgical debulking. Patients enrolled must complete at least 5 but no more than 6&#xD;
             cycles platinum/taxane adjuvant or interval debulking + chemotherapy (or chemotherapy&#xD;
             as per recommendations of NCCN guidelines, category 1 (IP chemotherapy included)).&#xD;
&#xD;
             (Patients who complete surgery/chemotherapy with a CA-125 &gt;20 U/mL pre-registration&#xD;
             have the option of being followed up to 2 months if serial CA-125 values continue to&#xD;
             decrease at a rate of CA-125 decrease of 50% per month.)&#xD;
&#xD;
          3. Successful manufacturing of 4 vials of Vigil™ vaccine.&#xD;
&#xD;
          4. Recovered from all clinically relevant toxicities related to prior protocol specific&#xD;
             therapies (including neuropathy to ≤Grade 2).&#xD;
&#xD;
          5. ECOG performance status (PS) 0-1.&#xD;
&#xD;
          6. Normal organ and marrow function as defined below:&#xD;
&#xD;
             Absolute granulocyte count ≥ 1,500/mm3 Absolute lymphocyte count ≥ 200/mm3 Platelets ≥&#xD;
             75,000/mm3 Total bilirubin ≤ 2 mg/dL AST(SGOT)/ALT(SGPT) ≤ 2x institutional upper&#xD;
             limit of normal Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          7. Patients must be off all &quot;statin&quot; drugs for ≥ 2 weeks prior to initiation of therapy.&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed protocol specific&#xD;
             consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Surgery involving general anesthesia, radiotherapy, or immunotherapy within 4 weeks&#xD;
             prior to randomization. Chemotherapy within 3 weeks prior to Vigil™ vaccine&#xD;
             administration. Steroid therapy within 1 week prior to vaccine administration.&#xD;
&#xD;
          2. Patient must not have received any other investigational agents within 4 weeks vaccine&#xD;
             administration.&#xD;
&#xD;
          3. Patients with history of brain metastases.&#xD;
&#xD;
          4. Patients with compromised pulmonary disease.&#xD;
&#xD;
          5. Short term (&lt;30 days) concurrent systemic steroids ≤ 0. 25 mg/kg prednisone per day&#xD;
             (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other&#xD;
             steroid regimens and/or immunosuppressives are excluded.&#xD;
&#xD;
          6. Prior splenectomy.&#xD;
&#xD;
          7. Prior malignancy (excluding nonmelanoma carcinomas of the skin and carcinoma in-situ&#xD;
             cervix) unless in remission for ≥ 2 years.&#xD;
&#xD;
          8. Kaposi's Sarcoma.&#xD;
&#xD;
          9. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
         10. Patients with known HIV.&#xD;
&#xD;
         11. Patients with chronic Hepatitis B and C infection.&#xD;
&#xD;
         12. Patients with uncontrolled autoimmune diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minal Barve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of &quot;bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell&quot; vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20.</citation>
    <PMID>22186789</PMID>
  </reference>
  <reference>
    <citation>Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, Lamont J, Bedell C, Wallraven G, Pappen BO, Roth A, Horvath S, Nemunaitis D, Kumar P, Maples PB, Senzer N. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver. Oncology. 2014;87(1):21-9. doi: 10.1159/000360993. Epub 2014 Jun 25.</citation>
    <PMID>24968881</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, Nemunaitis J. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Mol Ther. 2016 Aug;24(8):1478-83. doi: 10.1038/mt.2016.86. Epub 2016 Apr 25.</citation>
    <PMID>27109631</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, Pappen BO, LaNoue J, Kumar P, Nemunaitis D, Roth A, Nemunaitis J, Whiting S, Senzer N, Fletcher FA, Nemunaitis J. Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Mol Ther. 2015 Jun;23(6):1103-1109. doi: 10.1038/mt.2015.43. Epub 2015 Mar 19.</citation>
    <PMID>25917459</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve M, Manley M, Oliai BR, Murphy KM, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J. Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822.</citation>
    <PMID>28338569</PMID>
  </reference>
  <reference>
    <citation>Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.</citation>
    <PMID>33271095</PMID>
  </reference>
  <results_reference>
    <citation>Oh J, Barve M, Matthews CM, Koon EC, Heffernan TP, Fine B, Grosen E, Bergman MK, Fleming EL, DeMars LR, West L, Spitz DL, Goodman H, Hancock KC, Wallraven G, Kumar P, Bognar E, Manning L, Pappen BO, Adams N, Senzer N, Nemunaitis J. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol. 2016 Dec;143(3):504-510. doi: 10.1016/j.ygyno.2016.09.018. Epub 2016 Sep 24.</citation>
    <PMID>27678295</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov. Erratum in: Gynecol Oncol Rep. 2021 Mar 01;36:100740.</citation>
    <PMID>33364285</PMID>
  </results_reference>
  <results_reference>
    <citation>Rocconi RP, Stanbery L, Madeira da Silva L, Barrington RA, Aaron P, Manning L, Horvath S, Wallraven G, Bognar E, Walter A, Nemunaitis J. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines (Basel). 2021 Aug 12;9(8). pii: 894. doi: 10.3390/vaccines9080894.</citation>
    <PMID>34452019</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage III</keyword>
  <keyword>Stage IV</keyword>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

